The Journal of Nutritional Biochemistry
Volume 15, Issue 6 , Pages 358-365 , June 2004

Fish oil supplementation in F1 generation associated with naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats

  • João A. Pinto Jr

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Alessandra Folador

      Affiliations

    • Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
    • ,
  • Sandro J. Bonato

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Júlia Aikawa

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Ricardo K. Yamazaki

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Natalia Pizato

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Mirela Facin

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Hans Grohs

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Heloísa H.P. de Oliveira

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Katya Naliwaiko

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Anete C. Ferraz

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Anita Nishiyama

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Ricardo Fernandez

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • ,
  • Rui Curi

      Affiliations

    • Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
    • ,
  • Luiz C. Fernandes

      Affiliations

    • Department of Physiology, Biological Sciences Building, Federal University of Paraná, 81530-990, Curitiba PR, Brazil
    • Corresponding Author InformationCorresponding author. Tel.: (41) 361-1447; Fax: (41) 266-2042.

References 

  1. Barber MD, Ross JA, Fearon KCH. Cancer cachexia. Surg Oncol. 1999;8:133–141
  2. Costelli P, Tessitore L, Batetta B, Mulas MF, Spano O, Pani P, et al. Alterations of lipid and cholesterol metabolism in cachetic tumor-bearing rats are prevented by insulin. J Nutr. 1999;129:700–706
  3. Tisdale MJ. Cancer cachexia (metabolic alterations and clinical manifestations). Nutrition. 1997;13:1–7
  4. Giacosa A, Frascio F, Sukkar SG, Roncella S. Food intake and body composition in cancer cachexia. Nutrition. 1996;12:S20–23
  5. Plata-Salamán CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition. 2000;16:1009–1012
  6. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutr. 2000;16:1013–1014
  7. Tisdale MJ. Cancer anorexia and cachexia. Nutrition. 2001;17:438–442
  8. Cahlin C, Körner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia (the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-γ, and tumor necrosis factor-α evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia). Cancer Res. 2000;60:5488–5493
  9. Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi R. Insulin scretion in Walker 256 tumor cachexia. Am J Physiol. 1990;258:E1033–1036
  10. Tracey KJ, Lowry SF, Fahei TJ, Albert JD, Fong Y, Hesse D, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987;164:415–422
  11. Siddiqui RA, Williams JF. Interactions of vasopressin and prostaglandin E2 in the development of cancer cachexia. Med Sci Res. 1987;15:45–46
  12. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70:560S–569S
  13. Rose DP, Connoly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate. 1991;18:243–254
  14. Pandalai PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 1996;16:815–820
  15. Caygill CPJ, Charlett A, Hill MJ. Fat, fish oil and cancer. Br J Cancer. 1996;74:159–164
  16. Karmali RA. Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia. Nutr. 1996;12:S2–4
  17. Sauer LA, Dauchy RT, Blask DE. Mechanism for the antitumor and anticachetic effects of n-3 fatty acids. Cancer Res. 2000;60:5289–5295
  18. Sauer LA, Dauchy RT, Blask DE. Polyunsaturated fatty acids, melatonin, and cancer prevention. Biochem Pharmacol. 2001;61:1455–1462
  19. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther. 1999;83:217–244
  20. Helton WS, Espat NJ. Defining mechanisms of ω-3 fatty-acid activity. Nutrition. 2001;17:674–687
  21. Endres S, Ghorbani R, Kelley VE, Gerogilis K, Lonnemann G, van der Meer JWM, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320:265–271
  22. Meydani SN, Lichtenstein AH, Cornwall S, Meydani M, Goldin BR, Rasmussen H, et al. Immunological effects of National Cholesterol Education Panel Step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest. 1993;92:105–113
  23. Wigmore SJ, Fearon KCH, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci. 1997;92:215–221
  24. Barber MD, McMillan DC, Preston T, Ross JA, Fearon KCH. The metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish oil-enriched nutritional supplement. Clin Sci. 2000;98:389–399
  25. Fernandes LC, Carpinelli AR, Hell NS, Curi R. Improvement of cancer cachexia and decrease of Walker 256 tumor growth by insulin administration in rats. Cancer Ther Contr. 1991;1:259–268
  26. Moley JF, Morisson SD, Gorschboth CM, Norton JA. Body composition changes in rats with experimental cancer cachexia (improvement with exogenous insulin). Cancer Res. 1988;48:2784–2787
  27. Fernandes LC, Marques da Costa MM, Curi R. Metabolism of glucose, glutamine an pyruvate in lymphocytes from Walker 256 tumor-bearing rats. Braz J Med Biol Res. 1994;27:2539–2543
  28. Costa Rosa LFBP, Guimarães ARP, Safi DA, Curi R, Williams JF. Effect of various dietary fatty acids on enzyme activities of carbohydrate and glutamine metabolism and the metabolic responses of lymphocytes and macrophages during Walker-256 ascites cell tumor growth in rats. Biochem Mol Biol Int. 1993;29:33–45
  29. Reeds PJ, Hay SM, Dorward PM, Palmer RM. Stimulation of muscle growth by clenbuterol (lack of effect on muscle protein biosynthesis). Br J Nutr. 1986;56:249–256
  30. Yang YT, McElligot MA. Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J. 1989;261:1–10
  31. Chance WT, von Almen D, Benson D, Zhang F-S, Fisher JE. Clenbuterol decreases catabolism and increases hypermetabolism in burned rats. J Trauma. 1991;31:365–370
  32. Zeman RJ, Lundermann R, Etlinger JD. Clenbuterol, a β2–agonist, retards atrophy in denervated muscles. Am J Physiol. 1987;252:E152–155
  33. Chance WT, Cao L, Zhang F-S, Foley-Nelson T, Fisher JE. Muscle-sparing effect of clenbuterol in tumor-bearing rats maitained on total parenteral nutrition. Surg Forum. 1989;40:411–413
  34. Stallion A, Zhang F-S, Chance WT, Foley-Nelson T, Fisher JE. Reversal of cancer cachexia in rats by cimaterol and supplementatal nutrition. Surgery. 1991;110:678–684
  35. Stallion A, Foley-Nelson T, Chance WT, Fisher JE. Effects of increased B2-agonist dose in tumor-bearing animals. Nutr Cancer. 1993;20:251–260
  36. Williams ED, Karim SMM, Sandler M. Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated diarrhoea. Lancet. 1968;Jan 6;1(7532):22–23
  37. Lynch NR, Salomon JC. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst. 1978;62:117–121
  38. Homem-de-Bittencourt PI, Pontieri V, Curi R, Lopes OU. Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats. Braz J Med Biol Res. 1989;22:1039–1042
  39. Fulton AM. Inhibition of experimental metastasis with indomethacin (role of macrophages and natural killer cells). Prostaglandins. 1988;35:413–425
  40. Bennett B, Houghton J, Leaper DJ, Stamford IF. Cancer growth, response to treatment and survival time in mice (beneficial effect of the prostaglandin synthesis inhibition flurbiprofen). Prostaglandins. 1979;17:179–191
  41. Trinder P. Determination of blood glucose an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22:158–161
  42. Jung DH, Biggs HG, Moorehead WR. Colorimetry of serum cholesterol with use of ferric acetate/uranyl acetate and ferrous sulfate/sulfuric acid reagents. Clin Chem. 1975;21:1526–1530
  43. Young DS. Effects of Preanalytical Variables on Clinical Laboratory Tests. 2nd ed Washington, DC: AACC Press; 1997;
  44. Henry RJ. Clinical Chemistry (Principles and Technics). New York: Harper & Row; 1964; pp. 833–8
  45. Engle PC, Jones JB. Causes an elimination of erratic blanks in enzymatic metabolite assay involving the use of NAD+ in alkaline hydrazine buffers (improved conditions for the assay of L-glutamate, L-lactate, and other metabolites). Anal Biochem. 1978;88:475–484
  46. Winterbourn C, Gutteridge JMC, Halliwell B. Doxorubicin-dependent lipid peroxidation at low partial pressure of oxygen. J Free Rad Biol Med. 1985;1(1):43–49
  47. Miyasaka CK, Mendonça JR, Nishiyama A, Alves de Souza JA, Pires de Melo M, Pithon-Curi TC, et al. Comparative effects of fish oil given by gavage and fish oil-enriched diet on leukocytes. Life Sci. 2001;69:1739–1751
  48. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254
  49. Boyd NF, Martin LJ, Noffel M, Lockwood GA, Tritchler DL. A meta analysis of studies of dietary fat and breast cancer risk. Br J Cancer. 1993;68:627–636
  50. Caygill CPJ, Charlett A, Hill MJ. Fat, fish oil and cancer. Br J Cancer. 1996;74:159–164
  51. Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. 2001;58:283–288
  52. Collett ED, Davidson LA, Fan Y-Y, Lupton JR, Chapkin RS. n-6 and n-3 Polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol. 2001;280:C1066–1075
  53. Cowing BE, Saker KE. Polyunsaturated fatty acids and epidermal growth factor receptor/mitogen-activated protein kinase signaling in mammary cancer. J Nutr. 2001;131:1125–1128
  54. Dommels YEM, Alink GM, van Bladeren PJ, van Ommen B. Dietary n-6 and n-3 polyunsaturated fatty acids and colorectal carcinogenesis (results from cultured colon cells, animal models and human studies). Environ Toxicol Pharmacol. 2002;12:233–244
  55. Jiang WG, Bryce RP, Horrobin DF. Essential fatty acids (molecular and cellular basis of their anti-cancer action and clinical implications). Crit Rev Oncol Hematol. 1998;3:179–209
  56. Begin ME, Ells G, Das UN, Horrobin DF. Diferential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst. 1986;77:1053–1062
  57. Begin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst. 1988;80:188–194
  58. Begin ME, Ells G. Effects of C18 fatty acids on breast carcinoma cells cultured in vitro. Anticancer Res. 1987;7:215–218
  59. Subbaramaiah K, Zakin D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase (a novel approach in cancer prevention). Proc Soc Exp Biol Med. 1997;216:201–210
  60. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1 as well as Ptgs-2, reduces intestinal tumorigenesis in Mim mice. Cancer Res. 2000;60:4705–4708
  61. Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M, et al. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med. 2001;30:41–47
  62. Gately S. The contribution of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19:19–27
  63. Hilkens CM, Snijderset A, Snijdewint FG, Wierenga EA, Kapsenberg ML. Modulation of T-cell cytokine secretion by accessory-cell-derived products. Eur Respir J. 1996;22:90S–94S
  64. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2 (a novel target for cancer chemotherapy). J Cancer Res Clin Oncol. 2001;127:411–417
  65. Kirschenbaum A, Liu XH, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology. 2001;58:127–131
  66. Gelin J, Anderson C, Lundholm K. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 1991;51:880–885
  67. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 2000;1470:M69–78
  68. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306–1311
  69. Cassano G, Gasparre G, Susca F, Lippe C, Guanti G. Effect of prostaglandin E2 on the proliferation, Ca2+ mobilization and cAMP in HT-29 human colon adenocarcinoma cells. Cancer Lett. 2000;152:217–222
  70. Carbó N, López-Soriano J, Tarragó T, González O, Llovera M, López-Soriano FJ, et al. Comparative effects of β2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett. 1997;115:113–118
  71. Anderson PT, Hefferich WG, Parkhall LC, Meakel RA, Bergen WG. Ractopamine increases total and myofibrilar protein synthesis in cultured rat myotubes. J Nutr. 1990;120:1677–1683
  72. Emery PW, Rothwell NJ, Stock MJ, Winter PD. Chronic effects of β2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep. 1984;4:83–91
  73. Babit P, Booth FW. Clenbuterol prevents or inhibits loss of specific mRNAs in atrophying rat skeletal muscle. Am J Physiol. 1988;254:C657–660
  74. Benson DW, Foley-Nelson T, Chance WT, Zhang F-S, James JH, Fisher JE. Decreased myofibrilar protein breakdown following treatment with clenbuterol. J Surg Res. 1991;50:1–5
  75. Bartlett DL, Charland S, Torosian MH. Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer. 1994;73:1499–1504

PII: S0955-2863(04)00038-5

doi: 10.1016/j.jnutbio.2004.02.002

The Journal of Nutritional Biochemistry
Volume 15, Issue 6 , Pages 358-365 , June 2004

Article Tools